BioCryst Pharmaceuticals, Inc. (BCRX) stock forecast & analysis
8.47
NasdaqGS · USDDelayed by 15 minutes
Down: -0.05, -0.6%
8.45Down: -0.02, -0.2%
1 analysis
Latest analysis: · verdict locked
- Open
- 8.55
- Previous close
- 8.52
- Day range
- 8.38 – 8.62
- 52-week range
- 6.23 – 11.22
- Volume (shares)
- 3.51M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 255.54M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.55
- Market cap
- 2.16B
Market Scanner’s AI analysis of BioCryst Pharmaceuticals, Inc. (BCRX), updated November 2026: BCRX technicals showed price below key moving averages, while news highlighted new data for ORLADEYO and navenibart.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of BioCryst Pharmaceuticals, Inc. (BCRX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
BCRX technicals showed price below key moving averages, while news highlighted new data for ORLADEYO and navenibart.
Recent analyses for BioCryst Pharmaceuticals (BCRX) covered its technical trading position, noting the stock price was below both its 50-day and 200-day simple moving averages, with the 50-day SMA recently crossing below the 200-day SMA. The company's upcoming earnings report and recent announcements of new data for its products ORLADEYO and navenibart were also discussed.
BCRX news & sentiment
Social media discussion focused on new hereditary angioedema (HAE) data for ORLADEYO and navenibart, with commentary suggesting a shift in the investment narrative. News headlines highlighted the announcement of this new data, alongside technical analysis indicating the stock price was trading below key moving averages.
BCRX technical picture
BCRX price action showed the stock trading below its 50-day and 200-day simple moving averages, with the 50-day SMA recently crossing below the 200-day SMA. Momentum readings, as measured by MACD, were improving from prior lows but remained below zero.
Fundamentals
The analysis covered BioCryst Pharmaceuticals' valuation, noting its market capitalization and price relative to its 52-week range. Forward P/E and trailing price-to-sales multiples were also discussed, alongside the company's low beta indicating beta.
Factors discussed — upside
- Price is rising above its 10-day EMA.
- MACD momentum is improving from prior lows.
- New data for ORLADEYO and navenibart announced at ACAAI meeting.
- Commentary suggests new HAE data has changed the investment story.
Factors discussed — risks
- Price is below both 50-day and 200-day SMAs.
- 50-day SMA recently crossed below 200-day SMA (death cross).
- 50-day SMA is still sloping down.
- Limited detail available on the announced HAE data.
- technical analysis
- drug data
- upcoming earnings
- valuation metrics
Summary updated .
BCRX technical indicators
Common technical indicators for BCRX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 8.63 | Price below |
| 10-day exponential moving average | 8.18 | Price above |
| Relative strength index (14-day) | 54.82 | Neutral |
| MACD line (12/26/9) | -0.0849 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 7.57 – 8.64 | Price inside the bands |
Analyses
Recent BCRX.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-01 BCRX.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for BioCryst Pharmaceuticals, Inc.?
- Recent analyses highlighted that the price is rising above its 10-day EMA and that MACD momentum is improving from prior lows. Additionally, new data for ORLADEYO and navenibart were announced at the ACAAI meeting, and commentary suggests this new HAE data has changed the investment story.
- What are the risks for BioCryst Pharmaceuticals, Inc.?
- The analyses noted that the price is below both the 50-day and 200-day SMAs, with the 50-day SMA recently crossing below the 200-day SMA and still sloping downward. Furthermore, there is limited detail available on the announced HAE data.
- Is BioCryst Pharmaceuticals, Inc. bullish or bearish?
- Recent AI analyses of BioCryst Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted that the price is rising above its 10-day EMA and that MACD momentum is improving from prior lows. Additionally, new data for ORLADEYO and navenibart were announced at the ACAAI meeting, and commentary suggests this new HAE data has changed the investment story. Discussed risks: The analyses noted that the price is below both the 50-day and 200-day SMAs, with the 50-day SMA recently crossing below the 200-day SMA and still sloping downward. Furthermore, there is limited detail available on the announced HAE data. These are descriptive observations, not a recommendation.
- What is the latest sentiment on BioCryst Pharmaceuticals, Inc.?
- Social media discussion focused on new hereditary angioedema (HAE) data for ORLADEYO and navenibart, with commentary suggesting a shift in the investment narrative. News headlines highlighted the announcement of this new data, alongside technical analysis indicating the stock price was trading below key moving averages.
- How does Market Scanner analyse BioCryst Pharmaceuticals, Inc.?
- Every analysis of BioCryst Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for BioCryst Pharmaceuticals, Inc.?
Recent analyses highlighted that the price is rising above its 10-day EMA and that MACD momentum is improving from prior lows. Additionally, new data for ORLADEYO and navenibart were announced at the ACAAI meeting, and commentary suggests this new HAE data has changed the investment story.
What are the risks for BioCryst Pharmaceuticals, Inc.?
The analyses noted that the price is below both the 50-day and 200-day SMAs, with the 50-day SMA recently crossing below the 200-day SMA and still sloping downward. Furthermore, there is limited detail available on the announced HAE data.
Is BioCryst Pharmaceuticals, Inc. bullish or bearish?
Recent AI analyses of BioCryst Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted that the price is rising above its 10-day EMA and that MACD momentum is improving from prior lows. Additionally, new data for ORLADEYO and navenibart were announced at the ACAAI meeting, and commentary suggests this new HAE data has changed the investment story. Discussed risks: The analyses noted that the price is below both the 50-day and 200-day SMAs, with the 50-day SMA recently crossing below the 200-day SMA and still sloping downward. Furthermore, there is limited detail available on the announced HAE data. These are descriptive observations, not a recommendation.
What is the latest sentiment on BioCryst Pharmaceuticals, Inc.?
Social media discussion focused on new hereditary angioedema (HAE) data for ORLADEYO and navenibart, with commentary suggesting a shift in the investment narrative. News headlines highlighted the announcement of this new data, alongside technical analysis indicating the stock price was trading below key moving averages.
How does Market Scanner analyse BioCryst Pharmaceuticals, Inc.?
Every analysis of BioCryst Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh BCRX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.